Intralesional PV‐10 for in‐transit melanoma—A single‐center experience
Citations Over TimeTop 12% of 2016 papers
Abstract
Background and Objectives Patients with in‐transit melanoma metastasis have longer median survival than patients with distant metastatic disease. Furthermore, local disease control is an important endpoint for symptom management. The treatment of unresectable loco‐regional recurrence or in‐transit disease has been historically managed with a combination of treatments including surgery, radiotherapy, isolated limb infusion or perfusion as well as systemic therapies. Intralesional PV‐10 has been used at Peter MacCallum Cancer Centre since 2010, and the current report presents a retrospective analysis of patient outcomes, reporting the response rates, durability of responses, and observed toxicities. Methods Records were analyzed retrieving details of 19 patients treated with PV‐10 over a 4‐year period from 2010 to 2014. Medical records were reviewed for these patients and data extracted. Results Nineteen patients with in‐transit melanoma were treated with intralesional PV‐10 between 2010 and 2014. Disease control (complete or partial response or disease stability) was achieved in 68% of patients with 26% having a complete response. This was achieved with minimal associated toxicity. Conclusions PV‐10 is an effective, durable, well‐tolerated treatment tool with an acceptable side effect profile for the management of unresectable in‐transit melanoma. J. Surg. Oncol. 2016;114:380–384 . © 2016 Wiley Periodicals, Inc.
Related Papers
- → The Melanoma Epidemic: More Apparent Than Real?(1997)97 cited
- → Three-year analysis to determine prognostic factors affecting success in single-dose methotrexate treatment: a single-center experience(2018)2 cited
- → Relationship of cell-mediated cytotoxicity against melanoma cells to prognosis in melanoma patients(1978)41 cited
- → Inhibition of leukocyte migration in agarose by KC1 extracts of a human melanoma cell line grown in serum‐free medium(1975)16 cited
- → Preoperative diagnosis of malignant melanoma using the touch-fluorescence method(1993)8 cited